Report: Europe Emerging as Key Player in Global Marijuana Market
- A new report highlights Europe's marijuana market entering a pivotal phase driven by medical programs, international trade, and pharmaceutical manufacturing standards.
- Europe is the world's second-largest marijuana market by value, with expanding medical access and telemedicine accelerating patient adoption despite fragmented regulations.
- Germany leads reforms but faces rising imports and pricing pressures, while the UK market grows through private clinics despite challenges like affordability and stigma.
- The next 3-5 years are critical for Europe's cannabis policies, with increasing influence from global commodity factors such as trade, logistics, standards, and price competition.
(Photo credit: Ginja.club).
A new report from the Global Cannabis Network Collective and Whitney Economics says Europe’s marijuana market is entering a pivotal period, with medical access programs, international trade and pharmaceutical manufacturing standards helping reshape the region’s role in the global industry.
The report, What You Need to Know: EU & UK Cannabis Market Update, was released this week during Cannabis Europa 2026 in London. It examines marijuana markets across the European Union and the United Kingdom, with a focus on medical marijuana growth, telemedicine, imports, pricing pressure and regulatory changes.
According to the report, Europe ranks as the second-largest total addressable marijuana market in the world by value, despite a fragmented system of country-by-country regulations. The report says medical access programs are expanding, while telemedicine platforms are helping accelerate patient adoption in several markets.
Germany continues to lead much of Europe’s marijuana reform, though the report notes that rising imports and pricing pressure are beginning to change market dynamics. The UK medical marijuana market is also growing through private clinics and telemedicine, even as barriers remain related to affordability, physician education, stigma and limited participation from the National Health Service.
The report also points to the growing importance of EU GMP standards, which are becoming a key factor for companies seeking long-term access to European medical marijuana markets. Imports into Europe are increasing from Canada, Portugal, Latin America, Africa, Australia and other emerging supply regions.
Beau Whitney, chief economist of Whitney Economics and lead author of the report, said Europe is taking “a far more methodical and medically oriented approach to cannabis reform” than some earlier markets, arguing that the slower pace may create more structure and credibility over time.
The report includes analysis and commentary from contributors in Germany, Portugal, Spain, Czechia and the United Kingdom. It also highlights Portugal’s growing role as a cultivation and processing hub, Germany’s expanding telemedicine ecosystem, Spain’s medical access reforms and Czechia’s developing marijuana policies.
Pricing compression is also becoming a growing issue, according to the report. Germany is showing early signs of wholesale and retail price declines as imports rise, inventory expands and competition increases.
The report says the next three to five years could be defining for marijuana policy and market growth across Europe and the UK. It also argues that the industry is increasingly being shaped by factors common in other global commodities, including trade routes, logistics, manufacturing standards, supply economics and price competition.